Grand Pharmaceutical Group Limited
遠大醫藥集團有限公司*
(Incorporated in Bermuda with limited liability)
(Stock Code: 00512)

VOLUNTARY ANNOUNCEMENT

THE INVESTIGATIONAL NEW DRUG APPLICATION OF THE GROUP'S GLOBAL INNOVATIVE RDC DRUG TLX101 IN CHINA WAS ACCEPTED BY NMPA

This announcement is made by the board of directors (the "**Board**") of Grand Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

The Board is pleased to announce that the Investigational New Drug ("**IND**") application of TLX101, a global innovative radionuclide-drug conjugate ("**RDC**") of the Group for the treatment of glioblastoma multiforme, was officially accepted by the National Medical Products Administration of the People's Republic of China ("**NMPA**") recently. It is an important R&D progress of the Group in the field of nuclear medicine anti-tumor diagnosis and treatment.

TLX101 (^{131}I-IPA) is a radionuclide-small molecule conjugated therapeutic radiopharmaceutical product for the treatment of glioblastoma multiforme. It can pass through the blood-brain barrier entering the brain freely, and targets the overexpressed L-type amino acid transporter 1 (LAT-1) in glioblastoma to precisely irradiate cancer cells, and promote their apoptosis to achieve therapeutic effect. TLX101 has been granted orphan drug designation by the United States Food and Drug Administration (FDA) and is currently in Phase I/II clinical trials in Europe and Australia. Glioblastoma is the second most common brain tumor after meningioma, with an annual incidence of 3.2/100,000 and a 5-year survival rate of only 5%. Currently, the existing clinical treatment methods can only delay the progression of the tumor, but cannot avoid its recurrence, with unideal therapeutic effect. TLX101 is expected to be a pioneering therapeutic approach in the field of glioblastoma treatment.

By adhering to the treatment concept of integrated oncology diagnosis and treatment, the Group has reserved 13 innovative products in its nuclear medicine anti-tumor diagnosis and treatment segment (the IND applications of three products have been accepted by NMPA), covering 6 radionuclides including ^{68}Ga, ^{177}Lu, ^{131}I, ^{90}Y, ^{89}Zr and ^{99m}Tc as well as 8 cancers including liver cancer, prostate cancer and brain cancer. In terms of product types, it covers two types of radionuclide drugs for diagnosis and therapy, providing patients with multi-indication treatment options, multi-methods and integrated diagnosis and treatment of the world's leading anti-tumor

solutions.

The core product of the Group's nuclear medicine anti-tumor diagnosis and treatment segment YiGanTai® (易甘泰®) Yttrium-90 resin microsphere injections ("**YiGanTai®**") has been granted approval for commercialization by the NMPA in January 2022. The product provides a new and effective treatment modality for patients with liver malignancies in China, offering the opportunity for translational therapy and further surgical resection to achieve clinical cure, bridging the gap in the local treatment of liver metastases from colorectal cancer, improving the long-term treatment outcome of the Chinese patient population with liver cancer, and marking the arrival of a new international precision interventional treatment option in the field of liver malignancies in China. Since the official commercialization of YiGanTai® in May 2022, more than 50 hospitals have completed the nuclide transfer procedures, its official surgeries have been carried out in more than 30 hospitals in 17 provinces and cities in China. The follow-up results showed that the overall response of patients who take YiGanTai® surgery was satisfactory, and most patients achieved favorable clinical therapeutic effect and prolonged survival. At present, 5 patients have successfully achieved liver cancer tumor downstaging transform and took liver cancer resection, achieving clinical cure. Among patients who could be followed up for 3 months or more, the objective response rate of YiGanTai® for liver cancer was over 50%, and more than half of the patients had achieved tumor size remission. Among them, the symptoms of 5 patients were completely relieved with no resection required, and the disease control rate of the follow-up patients exceeded 95%, showing a remarkable therapeutic effect. In order to speed up the implementation and popularization of YiGanTai® microsphere precise interventional therapy in China, the Group relied on the high-quality reputation and practical experience accumulated overseas for the product over the years, assisted domestic doctors in conducting multiple personalized practical trainings by well-known overseas clinical experts. At present, it has trained more than 300 doctors in 70 hospitals on the theory or skills of YiGanTai® surgery, nearly 20 experts have obtained the operation qualification of independent surgery through strict one-to-one training by overseas experts, and many of them will soon obtain the qualification of training instructor, which will further accelerate the clinical popularization of YiGanTai® radioactive interventional operation. In 2023, with the adjustment of the pandemic prevention and control policy in China, the tumor diagnosis and treatment and the number of surgeries has gradually recovered, and the proportion of patients consulting YiGanTai® therapy in clinics has increased significantly. A number of hospitals have successively set up specialized YiGanTai® clinics to meet the clinical needs of patients, and YiGanTai® treatment is expected to show a continuous and rapid growth trend.

The nuclear medicine anti-tumor diagnosis and treatment platform is the Group's high-end technology platform in the field of anti-tumor. The Group has achieved a comprehensive strategic plan in the fields of R&D, production, sales, regulatory qualifications and established a complete industrial chain. The Group, together with Sirtex Medical Pty Limited, cooperated with Telix Pharmaceuticals Limited (ASX: TLX) and ITM Isotope Technologies Munich SE to establish a world-class tumor intervention R&D platform and a radionuclide-drug conjugate R&D platform. It has more than 400 employees, with more than 40% of them holding master's degrees and doctoral degrees, and is one of the most globalized segments of the Group. At the same time, the Group and Shandong University jointly established Grand Pharma - Shandong University Radiopharmaceutical Research Institute (遠大醫藥-山東大學放射藥物研究院) to jointly carry out R&D in RDC drugs on the basis of radionuclide research by the Laboratory Nuclear Medicine Research Institute (實驗核醫學研究所) of Shandong University.

The Group is advancing the construction of Class A qualification nuclide production platform in

an orderly manner. In the future, the Group will continue to strengthen its R&D and investment in the nuclear medicine anti-tumor diagnosis and treatment segment, enrich and improve the product pipeline and industrial layout, strive to achieve 10 nuclide products entering the clinical stage in the next 3 years, and realize the pipeline layout of more than twenty-five nuclear medicine anti-tumor diagnosis and treatment products, to form a nuclear medicine anti-tumor diagnosis and treatment product cluster with the core of YiGanTai® Yttrium-90 microsphere injections, continuously consolidating the Group's global leading position in the field of nuclear medicine anti-tumor diagnosis and treatment.

The Group always puts focus on the R&D of innovative products and advanced technologies. Adhering to a patient-centered and innovation-driven approach, the Group will continue to increase its investment in world-class innovative products and advanced technologies to meet unmet clinical needs and enrich its product pipeline and improve supply chain. The Group adopts the strategy of "global expansion and dual-cycle operation", forming a new pattern of domestic and international cycles that synergize with each other. In this way, the Group can make full use of its industrial advantages and R&D capabilities, to accelerate the commercialization process for innovative products and provide patients with more advanced and diverse treatment options globally.

Warning:

The approval of commercialization, manufacturing and sale of above products in China is subject to various factors with uncertainty. Shareholders and prospective investors of the Company are advised to exercise caution when dealing in the securities of the Company.

Note: The English transliteration of the Chinese name(s) in this announcement is included for information purpose only, and should not be regarded as the official English name(s) of such Chinese name(s).

By order of the Board
Grand Pharmaceutical Group Limited
Chairman
Dr. Tang Weikun

Hong Kong, 5 February 2023

As at the date of this announcement, the Board comprises four executive directors, namely, Dr. Tang Weikun, Dr. Shao Yan, Dr. Niu Zhanqi and Dr. Shi Lin, and three independent nonexecutive directors, namely, Ms. So Tosi Wan, Winnie, Dr. Pei Geng and Mr. Hu Yebi.

** For identification purpose only*